Research into Halotherapy has demonstrated its significant benefits for a range of chronic respiratory diseases, including asthma, COPD, bronchitis, and sinusitis. A notable study, conducted over ten years at a hospital complex in Tapolca, Hungary, involved 4,000 patients and revealed substantial long-term improvements in airway function and clinical outcomes for most participants. The therapy’s mechanism is based on the inhalation of dry sodium chloride aerosol, which helps clear mucus, reduce inflammation, and improve mucociliary clearance, a key issue in diseases like asthma and COPD. In a separate Russian study of 124 patients with chronic lung conditions, including asthma and bronchiectasis, participants reported significant improvement in symptoms after a series of Halotherapy sessions, with 60% of patients using no further medication post-treatment.
Halotherapy works by simulating the microclimate of a natural salt cave in a controlled environment known as a Halochamber. The process involves inhaling finely pulverized salt particles, which are small enough to reach the deepest parts of the lungs. This method has been shown to have bactericidal and anti-inflammatory effects on respiratory microflora, promoting lung health. The benefits are supported by research from various countries, with significant studies conducted by researchers like Simyonka (1989) and Rein & Mandell (1973). These studies underscore the therapeutic potential of salt therapy in improving lung function and reducing reliance on medications for chronic respiratory conditions.
